Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

antitrust investigation

EU flag

Celgene’s Vidaza wins wider approval for acute myeloid leukaemia

Elderly patients to gain access to cancer drug

- PMLiVE

Lundbeck sways NICE with new Brintellix data

Final draft guidance now backs the major depressive disorder drug

- PMLiVE

Europe’s health information systems to be modernised

Joint EC-WHO work will form a major strand of their renewedcollaboration

- PMLiVE

New EC health director general takes office

XavierPrats Monné will report to health commissioner Dr Vytenis Andriukaitis

- PMLiVE

Lundbeck to cut 1,000 jobs in major restructure

Losses will be felt in its headquarter functions and commercial operations

- PMLiVE

EU green light for Novartis’ skin cancer therapy

Swiss firm’s basal cell carcinoma treatment can now be launched across Europe

- PMLiVE

US filing aims to elevate Brintellix above its competition

Drug looking for an edge in the highly competitive major depressive disorder market

Bristol-Myers Squibb (BMS) building

BMS’ HIV combination Evotaz cleared in Europe

Comes after the firm recently announced it would shelve much of its virology unit

- PMLiVE

Lundbeck and Otsuka’s Rexulti set for August launch in US

Follows the antipsychotic drug's FDA approval on Friday

EU flag

Europe wants scientific advice to become pluralistic

Commission endeavours to create a new science committee and reject a single advisor model

- PMLiVE

Schultz takes Lundbeck helm after leaving Novo Nordisk

Former executive left Danish firm just days ago

- PMLiVE

Brintellix first antidepressant with cognition claim in Europe

Trial found it performed better than Lilly’s rival Cymbalta

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links